Your session is about to expire
← Back to Search
Intermittent Fasting for Chronic Lymphocytic Leukemia
N/A
Waitlist Available
Led By Nicol Macpherson, MD, PhD, FRCPC
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 3 months pre-intervention, monthly during intervention, 1 month post-intervention
Awards & highlights
Study Summary
This trial will compare 16/8 and 5:2 intermittent fasting methods in patients w/ chronic lymphocytic leukemia to find which is preferred and has greater effects on cancer cells, metabolism, inflammation, and gut microbiome.
Who is the study for?
This trial is for people under 85 with chronic B-cell leukemia or lymphoma, who have certain blood and health status markers. They must have completed a prior fasting study and not be on treatments that conflict with fasting.Check my eligibility
What is being tested?
The study compares two intermittent fasting methods (16/8 and 5:2) in their effects on cancer cells, metabolism, inflammation, and gut microbiome in patients who've done the 16/8 method before.See study design
What are the potential side effects?
Intermittent fasting may cause fatigue, hunger, irritability, headaches during fast periods. Long-term effects are still being studied but could include nutrient deficiencies if not managed properly.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ time frame: within 3 months pre-intervention, monthly during intervention, 1 month post-intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: within 3 months pre-intervention, monthly during intervention, 1 month post-intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in autophagy status
Change in inflammation
Change in lymphocyte count [ Time Frame: Within 3 months pre-intervention, monthly during intervention, 1 month post-intervention ]
+2 moreSecondary outcome measures
Change in gut microbiome (optional)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: 5:2 MethodExperimental Treatment1 Intervention
Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week ("normal days") and limiting total calorie intake to 800kcals per day ("fasting days") for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference.
Group II: 16/8 MethodActive Control1 Intervention
Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
5:2 Method (intermittent fasting regimen)
2023
N/A
~10
Find a Location
Who is running the clinical trial?
British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,505 Total Patients Enrolled
University of VictoriaOTHER
56 Previous Clinical Trials
11,485 Total Patients Enrolled
BC Cancer FoundationOTHER
17 Previous Clinical Trials
8,353 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You must have finished the "IF in CLL/SLL Study" (ClinicalTrials.gov Identifier: NCT04626843) and waited at least 3 months before joining this trial.You will likely need to start treatment for lymphoma within the next 3 months.You are pregnant.You have received treatment for lymphoma in the last 3 months.You have a body mass index (BMI) of 20 or higher.Your body mass index (BMI) drops below 18.5kg/m2 during the study.You take medication that requires you to eat food during the fasting period.
Research Study Groups:
This trial has the following groups:- Group 1: 16/8 Method
- Group 2: 5:2 Method
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this clinical study accepting volunteers aged 80 or above?
"As outlined in the eligibility criteria, this clinical trial has a minimum age requirement of 19 and an upper limit at 85 years old."
Answered by AI
Is this research opportunity accessible to interested volunteers?
"This trial is not enrolling participants presently, as confirmed on clinicaltrials.gov. Initially posted on March 1st 2021 and edited for the last time in January 23rd 2021, this study has ceased recruiting at present; however, 343 other medical trials are currently open to new registrants."
Answered by AI
Is it possible to sign up for participation in this scientific experiment?
"This clinical trial is recruiting 8 individuals who are between 19 and 85 years old, have been diagnosed with small lymphocytic lymphoma, possess a peripheral blood lymphocyte count of higher than 20 x 10^9/L, an hemoglobin level exceeding 90g/L, platelets greater than 90x10^9/L BMI >=20kg/m2 , ECOG Performance Status of at least 2 and has completed the "IF in CLL/SLL Study" (ClinicalTrials.gov Identifier: NCT04626843) followed by 3 months minimum ad libitum eating."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger